A pityriasis rosea-like eruption secondary to bacillus Calmette-Guérin therapy for bladder cancer.
The use of bacillus Calmette-Guérin (BCG) for the treatment of bladder cancer has been followed by reports documenting adverse reactions. Eruptions of the skin have been included (although not well described) in the list of side effects. We report a pityriasis rosea-like rash secondary to BCG therapy for bladder cancer. Although the treatment was interrupted because of this reaction, the medication was restarted later with only a mild transient recurrence of the eruption.
Honl
B A
BA
Dermatology Service, Brooke Army Medical Center, Fort Sam Houston, Texas, USA.
Keeling
J H
JH
Lewis
C W
CW
Thompson
I M
IM
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D001500:BCG Vaccine / Q000009:adverse effects*; D002278:Carcinoma in Situ / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000628:therapy; D003875:Drug Eruptions / Q000209:etiology*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017515:Pityriasis Rosea / Q000209:etiology*; D012008:Recurrence; D001749:Urinary Bladder Neoplasms / Q000628:therapy*; D014581:Urticaria / Q000209:etiology
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine